Market Tracker

05/25 5:16pm ET

Exelixis Inc (NASDAQ:EXEL)

6.23
Delayed Data
As of 4:00pm ET
 +0.08 / +1.30%
Today’s Change
3.08
Today|||52-Week Range
6.81
+10.46%
Year-to-Date
Exelixis' Kidney Cancer Drug Cabometyx Positive in Phase II
May 24 / Zacks.com - Paid Partner Content
Exelixis, Inc. Prepares for Blastoff
May 12 / MotleyFool.com - Paid Partner Content
Exelixis (EXEL) Worth a Look: Stock Up 8.1% in Session
May 16 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close6.15
Today’s open6.20
Day’s range6.17 - 6.38
Volume5,006,645
Average volume (3 months)4,838,373
Market cap$1.4B
Dividend yield--
Data as of 4:00pm ET, 05/25/2016

Growth & Valuation

Earnings growth (last year)+41.30%
Earnings growth (this year)-10.86%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+48.03%
P/E ratioNM
Price/Sales31.75
Price/Book--

Competitors

 Today’s
change
Today’s
% change
LXRXLexicon Pharmaceutic...+0.44+3.40%
ABCOAdvisory Board Co+0.46+1.44%
ARIAARIAD Pharmaceutical...+0.18+2.26%
DBVTDBV Technologies SA+0.18+0.56%
Data as of 4:14pm ET, 05/25/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)-$0.28
Annual revenue (last year)$37.2M
Annual profit (last year)-$169.7M
Net profit margin-456.63%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Michael M. Morrissey
Chief Financial Officer &
Executive Vice President
Christopher J. Senner
Corporate headquarters
South San Francisco, California

Forecasts